In summary, this is a novel mouse model of hyperuricemia established in two steps: knocking out of Uox by CRISPR/Cas9 system (prototypic Uox-/- mice) and allopurinol administration to improve their survivals up to 16 weeks (modified Uox-/- mice). Here, UOX is linked to hyperuricemia.